indacaterol (Arcapta)
Jump to navigation
Jump to search
Indications
Dosage
- once daily maintenance inhaler
capsules for dry powder inhaler:
- 75 mcg indacaterol inhalation powder
- capsules must be used with the neohaler device
Adverse effects
- black box warning: possible increased risk of asthma-related death
- cough (6-25%)
- oropharyngeal pain (2%)
- nasopharyngitis (5%)
- headache (5%)
- nausea (2%)
- drug adverse effects of adrenergic receptor agonists
- drug adverse effects of beta-adrenergic receptor agonists
- drug adverse effects of long-acting beta-adrenergic receptor agonists
- drug adverse effects of sympathomimetic(s)
Drug interactions
- consistent with those of other beta-2 adrenergic agonists
- concomitant use with MAO inhibitors, tricyclic antidepressants, & drugs that prolong the QTc interval may potentiate indacaterol's cardiovascular effects
- drug interaction(s) of beta-2 adrenergic receptor agonists with beta adrenergic receptor antagonists
- drug interaction(s) of beta-2 adrenergic receptor agonists with loop diuretics
- drug interaction(s) of beta-2 adrenergic receptor agonists with thiazide diuretics
Mechanism of action
- long-acting beta-2 adrenergic agonist
- bronchodilator, relaxation of bronchial smooth muscle
More general terms
References
- ↑ Wikipedia: Indacaterol http://en.wikipedia.org/wiki/Indacaterol
- ↑ Brooks M Medcape Oncology FDA Panel Backs Lower Dose of Indacaterol Maleate for COPD http://www.medscape.com/viewarticle/738653
- ↑ Prescriber's Letter 19(1): 2012 New Drug: Arcapta (Indacaterol) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=280104&pb=PRL (subscription needed) http://www.prescribersletter.com